Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
$9.63
+4.2%
$7.35
$2.32
$9.88
$499.81M2.93550,580 shs301,910 shs
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$33.61
+0.3%
$27.16
$10.81
$37.53
$485.26M0.51128,928 shs102,508 shs
Ocugen, Inc. stock logo
OCGN
Ocugen
$1.79
+1.7%
$1.21
$0.52
$1.90
$514.46M4.27.65 million shs7.36 million shs
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
$6.76
+1.0%
$5.22
$0.13
$1.04
$130.18M1.581.05 million shs128,600 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
+4.22%+3.22%+32.46%+20.22%+172.03%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
+0.33%-1.09%+15.50%+60.20%+110.19%
Ocugen, Inc. stock logo
OCGN
Ocugen
+1.70%+6.55%+73.79%+55.65%+86.81%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
+1.05%-12.21%+37.96%+37.40%+4,261.29%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
$9.63
+4.2%
$7.35
$2.32
$9.88
$499.81M2.93550,580 shs301,910 shs
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$33.61
+0.3%
$27.16
$10.81
$37.53
$485.26M0.51128,928 shs102,508 shs
Ocugen, Inc. stock logo
OCGN
Ocugen
$1.79
+1.7%
$1.21
$0.52
$1.90
$514.46M4.27.65 million shs7.36 million shs
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
$6.76
+1.0%
$5.22
$0.13
$1.04
$130.18M1.581.05 million shs128,600 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
+4.22%+3.22%+32.46%+20.22%+172.03%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
+0.33%-1.09%+15.50%+60.20%+110.19%
Ocugen, Inc. stock logo
OCGN
Ocugen
+1.70%+6.55%+73.79%+55.65%+86.81%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
+1.05%-12.21%+37.96%+37.40%+4,261.29%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
2.71
Moderate Buy$9.60-0.31% Downside
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
1.50
ReduceN/AN/A
Ocugen, Inc. stock logo
OCGN
Ocugen
2.50
Moderate Buy$6.00235.20% Upside
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest VIRI, OCGN, FULC, and INBX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/8/2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/8/2025
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
10/8/2025
Ocugen, Inc. stock logo
OCGN
Ocugen
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/27/2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
9/27/2025
Ocugen, Inc. stock logo
OCGN
Ocugen
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/19/2025
Ocugen, Inc. stock logo
OCGN
Ocugen
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$7.00
8/22/2025
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
JMP Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Perform
8/4/2025
Ocugen, Inc. stock logo
OCGN
Ocugen
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$7.00
7/30/2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetSector Perform$4.00 ➝ $5.00
7/29/2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutralBuy$4.00 ➝ $12.00
(Data available from 10/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
$80M6.51N/AN/A$4.51 per share2.14
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$200K2,433.36$115.90 per share0.29$9.23 per share3.64
Ocugen, Inc. stock logo
OCGN
Ocugen
$4.05M129.19N/AN/A$0.10 per share17.90
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/A$0.20 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-$9.73M-$1.22N/AN/AN/AN/A-31.05%-28.96%11/12/2025 (Estimated)
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$1.69B-$10.58N/AN/AN/AN/A-137.83%-76.31%11/13/2025 (Estimated)
Ocugen, Inc. stock logo
OCGN
Ocugen
-$54.05M-$0.20N/AN/AN/A-1,197.71%-255.25%-86.79%11/13/2025 (Estimated)
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
-$5.30M-$0.27N/AN/AN/AN/A-130.33%-115.00%N/A

Latest VIRI, OCGN, FULC, and INBX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-$2.92-$1.85+$1.07-$1.85N/A$1.30 million
8/1/2025Q2 2025
Ocugen, Inc. stock logo
OCGN
Ocugen
-$0.06-$0.05+$0.01-$0.05$0.35 million$1.37 million
7/29/2025Q2 2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-$0.29-$0.28+$0.01-$0.28N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
N/AN/AN/AN/AN/A
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
N/AN/AN/AN/AN/A
Ocugen, Inc. stock logo
OCGN
Ocugen
N/AN/AN/AN/AN/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
N/A
24.42
24.42
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
1.45
4.98
4.98
Ocugen, Inc. stock logo
OCGN
Ocugen
9.18
1.83
1.83
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/A
7.27
7.27

Institutional Ownership

CompanyInstitutional Ownership
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
89.83%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
82.46%
Ocugen, Inc. stock logo
OCGN
Ocugen
10.27%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
9.05%

Insider Ownership

CompanyInsider Ownership
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
7.00%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
17.09%
Ocugen, Inc. stock logo
OCGN
Ocugen
4.42%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
12.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
10054.09 million50.31 millionOptionable
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
16614.48 million12.01 millionOptionable
Ocugen, Inc. stock logo
OCGN
Ocugen
80292.30 million279.39 millionOptionable
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
519.26 million16.91 millionOptionable

Recent News About These Companies

Dogwood Therapeutics Inc (DWTX)
Dogwood prices 578,950 shares at $8.26 in registered direct offering
Dogwood announces conversion of existing $19.5M in debt to equity
DWTX Stock trading resumes
Dogwood Therapeutics, Inc. (DWTX)
DWTX Stock trading halted, volatility trading pause
Dogwood announces first patient dosed in Phase 2b trial on Halneuron
Dogwood Therapeutics faces potential Nasdaq delisting
Dogwood says low-dose IMC-2 treatment reduces long-COVID fatigue
DWTX: Phase 2 Long COVID Results Expected Soon
Dogwood Therapeutics Reports Q3 2024 Financial Results
Dogwood Therapeutics Announces Third Quarter 2024 Financial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Fulcrum Therapeutics stock logo

Fulcrum Therapeutics NASDAQ:FULC

$9.63 +0.39 (+4.22%)
Closing price 10/8/2025 04:00 PM Eastern
Extended Trading
$9.63 0.00 (0.00%)
As of 10/8/2025 05:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Inhibrx Biosciences stock logo

Inhibrx Biosciences NASDAQ:INBX

$33.61 +0.11 (+0.33%)
Closing price 10/8/2025 04:00 PM Eastern
Extended Trading
$33.64 +0.03 (+0.09%)
As of 10/8/2025 05:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Ocugen stock logo

Ocugen NASDAQ:OCGN

$1.79 +0.03 (+1.70%)
Closing price 10/8/2025 04:00 PM Eastern
Extended Trading
$1.78 -0.01 (-0.28%)
As of 10/8/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Virios Therapeutics stock logo

Virios Therapeutics NASDAQ:VIRI

$6.76 +0.07 (+1.05%)
As of 10/7/2025

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.